Enterprise Value

-20.63M

Cash

69.77M

Avg Qtr Burn

-21.98M

Short % of Float

5.59%

Insider Ownership

14.43%

Institutional Own.

43.73%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Korsuva IV (CR845 IV) Details
Pruritus with chronic kidney disease , Kidney disease

Approved

Quarterly sales

Oral Korsuva (difelikefalin) (CR845) Details
Pruritus with chronic kidney disease , Chronic kidney disease

Phase 3

Update

Oral Korsuva (difelikefalin) (CR845) Details
Chronic pruritus, Pruritus associated with notalgia paresthetica

Phase 2/3

Data readout

Oral Korsuva (difelikefalin) (CR845) Details
Chronic liver disease, Liver disease, Chronic pruritus, Hemophilia, Blood disorder

Failed

Discontinued

Oral Korsuva (difelikefalin)(CR845) Details
Inflammatory disease, Skin disease/disorder, Atopic dermatitis, Atopic pruritus

Failed

Discontinued